GMR Solutions (GMRS) Q1 2026 earnings review
Massive Profit Surge Masks Underlying Volume and Cash Flow Weakness
GMR delivered a headline-grabbing 180% YoY surge in Net Income, flipping EPS to a positive $0.28. But a look under the hood reveals a lower-quality beat. The revenue growth (6.6%) was driven entirely by a nearly 8% hike in pricing, while actual ground transport volumes shrank. Furthermore, the massive profit expansion did not translate to cash—Operating Cash Flow plunged 32% due to mounting receivables. Management is leaning heavily on price hikes and interest expense reductions, a strategy that has limits.
🐂 Bull Case
Net revenue per ambulance transport jumped from $1,260 to $1,360 (+7.9%), easily offsetting flat volumes and driving top-line growth.
Net interest expense dropped nearly 27% to $83.2M from $113.7M last year. Coupled with a $250M preferred stock redemption, the balance sheet is rapidly deleveraging.
🐻 Bear Case
Despite Net Income tripling, Operating Cash Flow fell 32% ($128.7M vs $189.3M) driven by a severe $64.8M buildup in accounts receivable.
Total ambulance transports actually declined slightly (1.042M vs 1.052M), with core ground transports shrinking. Growth is coming strictly from price, not demand.
⚖️ Verdict: ⚪
Neutral. The bottom-line explosion looks phenomenal, but the foundation is cracking. Shrinking transport volumes and deteriorating cash conversion suggest the operational engine is stalling, even as financial engineering bolsters the P&L.
Key Themes
Earnings Fact vs. Cash Flow Fiction
The most glaring red flag in this report is the cash flow divergence. Net income exploded by $68.3M YoY, yet cash from operations fell by $60.6M. The culprit is working capital: Accounts Receivable consumed $64.8M in cash, and a reduction in accrued wages/benefits drained another $73.2M. If revenue is growing but collections are stalling, the pricing power narrative loses its luster.
Aggressive Price Realization
Net transport revenue per ambulance transport rose 7.9% to $1,360. With a stable payor mix (Medicare 25%, Commercial 57%), this suggests aggressive and successful rate negotiations with commercial insurers. This pricing lever is currently doing 100% of the heavy lifting for top-line growth.
Decelerating Core Growth and Volume Shrinkage
Same-market revenue growth is decelerating sharply, dropping from 14.9% in 25Q1 to just 7.9% in 26Q1. More concerningly, total ambulance transports fell YoY. Ground transports (the bulk of the business) dropped by roughly 10,000 encounters. A healthcare logistics provider cannot shrink its way to long-term prosperity.
Below-the-Line Earnings Boost
Operating income only grew 23% ($218.9M vs $177.9M). The massive 180% net income growth was artificially inflated by a $30.5M YoY reduction in interest expense and the absence of a $14.1M impairment charge from last year. This is a one-time reset, not a sustainable operational run-rate.
Nurse Navigation Tech Expansion
A massive bright spot in utilization: Nurse Navigation encounters surged 46.7% YoY (28,122 vs 19,171). This specific triage/tech intervention is a critical evolution, allowing GMR to monetize non-transport patient routing and reduce uncompensated dry-runs.
Stable Weather Macro
Air medical transport is highly sensitive to macro weather patterns. The weather cancellation rate for emergent air transports remained stable and slightly improved to 17.1% (from 17.9%), removing environmental headwinds from the flight segment, which saw a slight volume uptick.
Other KPIs
Up 9.7% YoY. This strips out the noise of the massive interest expense reduction and lack of impairment charges, providing a much clearer picture of actual operating leverage. Margin expansion here is solid but modest compared to the Net Income hyperbole.
Healthy position consisting of $426.1M in cash and $691.6M in ABL capacity. However, cash balances dropped sequentially from $609.3M at year-end 2025, largely due to the $250M preferred stock redemption and weak operating cash flow.
Guidance
Accelerating. The midpoint of $6.035B implies an average quarterly run-rate of $1.50B for the rest of the year, a sequential step up from the $1.45B delivered in Q1. Management clearly expects either volume recovery or further price realization in the back half of the year.
Decelerating slightly. Q1 delivered $305M. To hit the $1,165M midpoint, the remaining three quarters only need to average $286M. This suggests management expects margin compression or higher costs (fuel, wages) later in the year.
Stable. Suggests total capital outlay of roughly $315M for the year. Q1 combined CapEx and aircraft financing was $79M, exactly on pace with this annualized target.
Key Questions
Accounts Receivable Buildup
What specifically drove the $64.8M headwind in Accounts Receivable? Are we seeing pushback or delayed payments from commercial payers in response to the 8% higher revenue per transport?
Ground Transport Contraction
Ground transports shrank by roughly 10,000 encounters YoY. Is this an intentional exit from low-margin/rural markets, lost market share to competitors, or a macro decline in emergency volume?
EBITDA Guidance Conservatism
Q1 Adjusted EBITDA was $305M. Your full-year midpoint implies a step-down to a $286M quarterly average for the rest of the year. What specific cost headwinds are you forecasting that explain this margin deceleration?